Description: Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.
Home Page: www.prostatypegenomics.com
Industrivägen 19
Solna,
171 48
Sweden
Phone:
46 08 20 87 00
Officers
| Name | Title |
|---|---|
| Mr. Fredrik Persson | CEO & MD |
| Mr. Michael af Winklerfelt | CFO & COO |
| Ms. Emelie Berglund | Chief Technology Officer |
| Mr. Nicklas Rosendal | Communications Director |
| Joakim Soderin | Chief Auditor |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1393 |
| Price-to-Sales TTM: | 34.5922 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |